Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
CEBIOTEX logo — Providing solutions for patients with cancer by helping surg...

CEBIOTEX

Providing solutions for patients with cancer by helping surgeons in their oncological interventions.

Founded 2015 Spain Spain 8 employees Equity Crowdfunding Total: $3.58M Biotechnology, Health Care +2

General Information

Company Name CEBIOTEX
Founded Year 2015
Location Spain Spain
Founders / Decision Makers
Team member
Employees 8
Industries Biotechnology, Health Care, Life Sciences +1
Funding Stage Equity Crowdfunding
Social

BounceWatch is an independent company data service, not affiliated with CEBIOTEX. To contact CEBIOTEX, visit cebiotex.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does CEBIOTEX compare?

A PDF of CEBIOTEX and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting CEBIOTEX soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About CEBIOTEX

CEBIOTEX is a biotechnology startup based in Spain that aims to provide solutions for cancer patients by aiding surgeons in their oncological interventions. The company utilizes nanofiber engineering to develop a medical product that can be infused with multiple agents, particularly beneficial for low water solubility drugs. CEBIOTEX's proprietary technology enables the production of biocompatible-biodegradable membranes protected by several patents in EU, USA, and China. Their primary focus is on addressing the medical need in oncology by enhancing local control of cancer after surgery to reduce recurrence and spreading of tumor cells. Their first product, CEB-01, incorporates a nanofiber membrane and the chemotherapy drug SN-38. Notably, it has received Orphan Drug Designation (ODD) in the EU for Soft Tissue Sarcoma (STS). CEB-01 is designed to be placed over the surgical bed immediately after tumor removal, delivering SN-38 locally during the postoperative period when no other therapy can be administered. The company has achieved significant milestones, including the completion of preclinical work, GMP certification for manufacturing, and regulatory approvals to initiate clinical trials at Hospital de Sant Pau in Barcelona, which have shown promising results. Founded in 2012, CEBIOTEX began as a spin-off of UPC and Hospital Sant Joan de Déu de Barcelona. The startup recently secured a €750.00K equity crowdfunding investment at 23 December 2020, reflecting investor confidence in the company's innovative approach to addressing critical medical needs in cancer treatment. The intersection of biotechnology, healthcare, and manufacturing underscores its potential for disrupting the oncology space and improving patient outcomes.

Business keywords: Cancer treatment, Nanofiber engineering, Medical product development, Drug delivery technology, Oncology, Chemotherapy innovation, Surgical oncology, Orphan drug designation, Clinical trials, Biomedical technology, Biodegradable membranes, GMP certification, Hospital partnerships, Spin-off company, Preclinical research

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Equity Crowdfunding €750.00K -
23 Dec 2020
Equity Crowdfunding €680.40K 1
Capital Cell
08 Jan 2018
Series A €1.80M 5
Inveready Ship2B
Inveready, Ship2B +3
16 Feb 2017
Grant €50.00K 1
EASME - EU Executive Agency for SMEs
01 Feb 2017
Seed Round Undisclosed 1
Ship2B
Ship2B
15 Dec 2016
Equity Crowdfunding €300.00K 1
Capital Cell
31 May 2016

CEBIOTEX Alternatives & Competitors

View All Alternatives
CEBIOTEX vs
SciTech Development, Inc.
SciTech Development, Inc. United States

SciTech Development is a Specialty Pharmaceutical Company dedicated to advancing breakthrough cancer...

Venture round
8 employees
Biotechnology, Life Sciences
CEBIOTEX vs
Onena Medicines
Onena Medicines Switzerland

AI-centric preclinical company discovering and developing novel biopharmaceuticals to treat cancer a...

9 employees
Biotechnology, Health Care
CEBIOTEX vs
Targazyme
Targazyme

Targazyme Inc. is a San Diego-based, clinical-stage biopharmaceutical company developing novel enzym...

Series A
11 employees
Biopharma, Biotechnology
View all alternatives

FAQ About CEBIOTEX

Providing solutions for patients with cancer by helping surgeons in their oncological interventions.
CEBIOTEX was founded in 2015.
CEBIOTEX is headquartered in Spain.
CEBIOTEX operates in Biotechnology, Health Care, Life Sciences and Manufacturing. Its work centres on Cancer treatment, Nanofiber engineering, Medical product development and Drug delivery technology.
CEBIOTEX has approximately 8 employees.
CEBIOTEX has completed 6 funding rounds, raising a total of $3.58M. The latest funding stage is Equity Crowdfunding.
Top alternatives and competitors to CEBIOTEX include SciTech Development, Inc., Onena Medicines, Targazyme, Juventas Cell Therapy Corp., Cytimmune Sciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CEBIOTEX and SciTech Development, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for CEBIOTEX, https://bouncewatch.com/company/cebiotex, updated 31 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout